Subscribe To
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to lorundrostat with placebo-adjusted systolic BP reduction of 16.7 mmHg with 50mg once-daily dosing Additional clinical trial expected to begin in first half of 2023 RADNOR, Pa., March 04, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. […] The post Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2...
Read More
Content Topics
Mineralys
Therapeutics
Presents
Positive
Lorundrostat
Results
Target htn
Acc 23 wcc
Forex
Posted: Mar 4 2023, 21:30
Author Name: forextv
Views: 102863